These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12934102

  • 1. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
    Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA.
    Oncogene; 2003 Aug 21; 22(35):5427-35. PubMed ID: 12934102
    [Abstract] [Full Text] [Related]

  • 2. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S.
    Anticancer Res; 2006 Aug 21; 26(1A):259-65. PubMed ID: 16475706
    [Abstract] [Full Text] [Related]

  • 3. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 4. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 01; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 5. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M.
    Oncogene; 2001 Jul 12; 20(31):4128-37. PubMed ID: 11464279
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S, Schüller A, Frese-Schaper M, Gugger M, Schmid RA.
    Anticancer Res; 2009 Aug 12; 29(8):2905-11. PubMed ID: 19661294
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.
    Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
    Nesterov A, Nikrad M, Johnson T, Kraft AS.
    Cancer Res; 2004 Jun 01; 64(11):3922-7. PubMed ID: 15173003
    [Abstract] [Full Text] [Related]

  • 12. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
    Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A.
    Br J Cancer; 2003 Jul 07; 89(1):206-14. PubMed ID: 12838325
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ.
    Cancer Res; 2005 Jun 01; 65(11):4902-8. PubMed ID: 15930312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.